Fig. 2From: Molecular testing for cytologically suspicious and malignant (Bethesda V and VI) thyroid nodules to optimize the extent of surgical intervention: a retrospective chart reviewMutation distribution in the intervention group, using ThyGenext® or ThyroseqV3®. The most prevalent mutation type was BRAF V600E, a high-risk mutation. *The one case with a TERT mutation had a co-mutation of BRAF V600EBack to article page